Please use this identifier to cite or link to this item:
|Title:||The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment|
|Citation:||Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.816|
|Publisher:||American Society of Hematology|
|Conference Name:||56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)|
|Susan Branford, David T Yeung, David M Ross, Wendy T Parker, Jodi Braley, John F Seymour, and Timothy P. Hughes|
|Rights:||© 2014 by The American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.